Jinling Pharmaceutical (000919.SZ) subsidiary's arotinolol hydrochloride API approved for marketing.
Jinling Pharmaceutical (000919.SZ) announced that its controlling subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., recently received the "Chemical API Marketing Application Approval Notice" for arotinolol hydrochloride issued by the National Medical Products Administration. Arotinolol hydrochloride is a receptor blocker that blocks both alpha and beta receptors, and its formulation products are mainly used to treat essential hypertension (mild to moderate), angina pectoris, and other diseases.
Jinling Pharmaceutical (000919.SZ) announced that its controlling subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., recently received the "Marketing Application Approval Notice for Chemical Active Pharmaceutical Ingredients" for arotinolol hydrochloride issued by the National Medical Products Administration. Arotinolol hydrochloride is a receptor blocker that blocks both alpha and beta receptors, and its formulation products are mainly used to treat essential hypertension (mild to moderate), angina pectoris, and other diseases.
Related Articles
SAM WOO CONS (03822) awarded construction engineering contract
HSBC HOLDINGS (00005) spent HKD 93.2413 million to repurchase 580,000 shares on September 21.
LX TECHNOLOGY (02436) repurchased 240,000 shares for HK$4.8626 million on September 22.
SAM WOO CONS (03822) awarded construction engineering contract
HSBC HOLDINGS (00005) spent HKD 93.2413 million to repurchase 580,000 shares on September 21.
LX TECHNOLOGY (02436) repurchased 240,000 shares for HK$4.8626 million on September 22.
